BioSpace News Archive

G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that COSELA® (trilaciclib) has been recommended as a myeloid supportive agent in the updated American Society of Clinical Oncology (ASCO) small cell lung cancer (SCLC) guidelines for patients with untreated or previously treated extensive-stage small cell lung cancer (ES-SCLC) who are undergoing treatment with chemotherapy or chemoimmunotherapy.

Gradalis, Inc. announced that it will host a virtual KOL discussion on the Vigil® platform entering Phase 2 for platinum-sensitive recurrent ovarian cancer on Wednesday, October 25, 2023 at 11:00am ET.

The results of the PROTECT clinical trial shared today by Sanofi and presented at the International Society for Pediatric and Adolescent Diabetes (ISPAD) annual conference demonstrate that TZIELD, the first disease-modifying therapy available to delay clinical T1D in people at risk of developing the disease, can also be effective in newly diagnosed children and adolescents ages 8-17.

Sionna Therapeutics today announced that the company’s data will be presented at the 2023 North American Cystic Fibrosis Conference (NACFC) to be held November 2-4 in Phoenix, Arizona.

Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of November.

AVS (Amplitude Vascular Systems, Inc), announced today it will present data from its POWER PAD I clinical trial at the Transcatheter Cardiovascular Therapeutics (TCT) conference.

Cognito Therapeutics announced today it has been selected to present clinical data as a late-breaker abstract from its proprietary investigational disease-modifying therapy in patients with Alzheimer’s Disease, at the 16th Annual Clinical Trials on Alzheimer’s Disease (CTAD) conference taking place in Boston and online, October 24-27, 2023.

Spruce Biosciences, Inc. today announced completion of target enrollment of 72 patients and closure of screening in the CAHmelia-203 clinical trial evaluating tildacerfont for the treatment of adult classic congenital adrenal hyperplasia (CAH) and provided updated anticipated milestones.

Checkpoint Therapeutics, Inc. today announced the publication of results from the multicenter, multiregional, pivotal trial evaluating cosibelimab, a differentiated and potential best-in-class anti-PD-L1 antibody, in patients with metastatic cutaneous squamous cell carcinoma (“cSCC”), in the Journal for ImmunoTherapy of Cancer (JITC).

SeaStar Medical Holding Corporation announces receipt of U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for its patented, first-in-class, cell-directed Selective Cytopheretic Device (SCD) for use with patients in the hospital intensive care unit (ICU) with acute kidney injury (AKI).